Study of RO6807952 in Patients With Diabetes Mellitus Type 2
Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the
efficacy and safety of RO6807952 in patients with diabetes mellitus type 2 inadequately
controlled with metformin alone. Patients will be randomized to receive doses of RO6807952,
placebo, or liraglutide. The anticipated time on study treatment is 12 weeks.